Related Experiment Video
Updated: Nov 18, 2025

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
PDLIM2 repression by ROS in alveolar macrophages promotes lung tumorigenesis
Abstract:
One of the most fundamental and challenging questions in the field of cancer is how immunity is transformed from tumor immunosurveillance to tumor-promoting inflammation. Here, we identified the tumor suppressor PDZ-LIM domain-containing protein 2 (PDLIM2) as a checkpoint of alveolar macrophages (AMs) important for lung tumor suppression. During lung tumorigenesis, PDLIM2 expression in AMs is downregulated by ROS-activated transcription repressor BTB and CNC homology 1 (BACH1). PDLIM2 downregulation leads to constitutive activation of the transcription factor STAT3, driving AM protumorigenic polarization/activation and differentiation from monocytes attracted from the circulation to suppress cytotoxic T lymphocytes and promote lung cancer. PDLIM2 downregulation also decreases AM phagocytosis. These findings establish ROS/BACH1/PDLIM2/STAT3 as a signaling pathway driving AMs for lung tumor promotion.
Insights
Lung tumor suppressor PDZ-LIM domain-containing protein 2 (PDLIM2) is downregulated in alveolar macrophages (AMs) during cancer. This promotes tumor growth by activating STAT3 signaling and reducing AMs ability to fight cancer.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- The transition from tumor immunosurveillance to tumor-promoting inflammation is a critical challenge in cancer research.
- Alveolar macrophages (AMs) play a complex role in lung tumorigenesis, capable of both suppressing and promoting tumor growth.
Purpose of the Study:
- To identify key regulators of AM function during lung tumorigenesis.
- To elucidate the molecular mechanisms by which AMs shift from a tumor-suppressive to a tumor-promoting phenotype.
Main Methods:
- Investigated the role of PDZ-LIM domain-containing protein 2 (PDLIM2) in lung tumor suppression.
- Analyzed the regulation of PDLIM2 expression by ROS-activated transcription repressor BTB and CNC homology 1 (BACH1).
- Examined the downstream effects of PDLIM2 downregulation on STAT3 activation, AM polarization, monocyte differentiation, and phagocytosis.
Main Results:
- PDLIM2, a tumor suppressor, acts as a checkpoint for AMs in lung cancer.
- During lung tumorigenesis, reactive oxygen species (ROS) activate BACH1, which downregulates PDLIM2 expression in AMs.
- PDLIM2 downregulation leads to constitutive STAT3 activation, promoting AM protumorigenic polarization, monocyte recruitment, suppression of cytotoxic T lymphocytes, and reduced AM phagocytosis.
Conclusions:
- The ROS/BACH1/PDLIM2/STAT3 signaling axis is identified as a critical pathway driving AMs towards a tumor-promoting role in lung cancer.
- Restoring PDLIM2 function in AMs may represent a potential therapeutic strategy for lung cancer.
Related Concept Videos
Abnormal Proliferation
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

